Tango Therapeutics, Inc.
TNGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 15.2% | 46.9% | -32.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -340.1% | -306% | -440.3% | -154.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -309.7% | -278.5% | -435.1% | -157.2% |
| EPS Diluted | -1.19 | -1.08 | -1.23 | -0.94 |
| % Growth | -10.2% | 12.2% | -30.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |